Ọgwụ 1: Precursor Peptide ịdị ọcha & Iguzosi ike n'ezi ihe nke usoro
Njikọ Peptide site na Synthesis Peptide siri ike (SPSS) ma ọ bụ gbaa ụka microbial na-ebute adịghị ọcha nwere njikọ chiri anya. Na ngwa rediopharmaceutical, obere peptide adịghị ọcha nwere ike gbagọọ kinetics radiolabeling nke ukwuu ma ọ bụ mpi ozugbo na peptide lekwasịrị anya maka njikọ nnabata tumor..
Ntugharị igodo: A 95% mkpokọta ịdị ọcha na CoA enweghị isi ma ọ bụrụ na nke fọdụrụ 5% nwere usoro ihichapụ nke na-ekekọta na-ahọrọghị ya ma ọ bụ ihe mgbochi na-egbochi rediolabeling pH na nhazi..
Ụdị ọdịda nkịtị
- Na-emekọ ihe mkpochapụ adịghị ọcha (n-1, n-2): Iberibe usoro gbajiri agbaji ewepụtara n'oge usoro njikọ (eg., na mpaghara ogologo njikọ nke PSMA-617 ma ọ bụ usoro octapeptide cyclic nke DOTA-TATE) na-ekekọrịtakarị hydrophobicity nso-ihe yiri ya na peptide ogologo zuru oke, na-emekọ ihe ọnụ n'oge ọkọlọtọ Reverse-Phase HPLC (RP-HPLC).
- Amino Acid Racemization: Epimerization na ihe mkpofu na-adịkarị mfe ịgba ọsọ (dị ka Cysteine , Tryptophan, ma ọ bụ Histidine) na-agbanwe mgbanwe akụkụ atọ, ibelata njikọ nnata ma ọ bụ na-emebi ohere chelator.
- Trifluoroacetic acid (TFA) Mgbochi nsi: TFA fọdụrụnụ nke fọdụrụ na mmanya mmanya na-agbanwe agbanwe na-agbanwe pH nhazi n'oge akara redio ma na-ebute nsị cellular na mgbada na vitro na in vivo assays..
- Nnukwu Mass vs. Netwọk ọdịnaya Peptide adabaghị: Uzuzu peptide lyophilized nwere mmiri fọdụrụnụ, counterions, na nnu. Ịdabere na oke ibu karịa ọnụọgụ peptide net na-ebute ngụkọ ọrụ molar na-ezighi ezi n'oge ịdenye aha..
Nyocha nyocha akwadoro
- Orthogonal RP-HPLC / Profaịlụ UHPLC: Jiri usoro nkwụkọ aka kwụ ọtọ (dị ka ogidi C18 na Phenyl-Hexyl) na obere pH na-anọpụ iche iji dozie diastereomers na-ekpochapụ anya na usoro nhichapụ.
- Mass Spectrometry dị elu (LC-ESI-HRMS): Kwenye ezi monoisotopic mass na usoro usoro profaịlụ adịghị ọcha ruo 0.1% oke mpaghara.
- Ion Chromatography (IC): Gbanwee ọnụ ọgụgụ ndị fọdụrụnụ (TFA, acetate, chloride) iji kwado ntughari ngbanwe zuru oke.
- Amino Acid Analysis (AAA): Lelee ọdịnaya peptide net nke ọma iji mee ka stoichiometry ziri ezi n'oge mmeghachi omume akara redio..
Ebe nkọwapụta ndị na-ere ahịa
Mgbe ị na-eguzobe Nkwekọrịta Ọdịmma maka ọkọnọ precursor omenala, manye usoro ntọala ntọala ndị a:
- RP-HPLC ịdị ọcha: ≥ 95.0% maka nyocha mbụ; ≥ 98.0% maka batches na-enyere IND/ụlọ ọgwụ.
- Otu kacha adịghị ọcha: < 0.5% mpaghara site na RP-HPLC.
- Ọdịnaya TFA fọdụrụnụ: < 1.0% w/w (na-ahọrọ acetate ma ọ bụ hydrochloride mgbanwe).
- Ọdịnaya Peptide Net: AAA kọwara ya (na-abụkarị 80-90% maka nnu lyophilized).
Peptide Synthesis Mgbe ị na-azụta usoro ebumnuche gbagwojuru anya - dị ka PSMA-617 ma ọ bụ DOTA-TATE precursors - na-ewepụta nkwekọrịta ịdịmma ndị na-ebubata ihe siri ike maka omenala peptide njikọ na nyocha QC na-achọpụta na profaịlụ HPLC orthogonal na protocol mgbanwe agbanweela nke ọma tupu ahapụpụta ya..
Ọgwụ 2: Nkewa saịtị njikọ & Chelator iguzosi ike n'ezi ihe
Chelators bifunctional-dị ka DOTA, Jiri, DOTAGA, ma ọ bụ NODA-MP-NCS - na-ejikọta ya na ọkpụkpụ azụ peptide ma ọ bụ n'oge njikọ siri ike ma ọ bụ site na bioconjugation post-synthetic.. Regioselective nkenke bụ ihe kacha mkpa: onye chelator nke etinyere na ihe fọdụrụ na Lysine ma ọ bụ ihe fọdụrụ nke Cysteine nwere ike ịkwụsị kpamkpam ọrụ ndu..
[Ebumnuche Peptide azụ] [Bifunctional Linker] [Macrocyclic Chelator (ENDOW/MARA)]
Ụdị ọdịda nkịtị
- Regioisomeric ambiguity: Njikọ na-abụghị nke akọwapụtara n'oge bioconjugation (eg., Mgbakwunye DOTA na ụdọ akụkụ Lysine ma ọ bụ ọnọdụ amine njikọ na DOTA-TATE na PSMA-617 na-arụ), na-emepụta regioisomers nwere kinetics na-ejikọta nke ukwuu.
- Over-Conjugation (Multi-Chelator mgbakwunye): Nchedo nke n'akụkụ ezughị ezu na-ebute peptides na-ebu Peptides sịntetik akụkụ abụọ ma ọ bụ karịa chelator (di-DOTA ma ọ bụ tri-DOTA ụdị), nke na-agbanwe biodistribution na pharmacokinetics.
- Mmebi mgbanaka Hydrolytic: Hydrolysis ma ọ bụ mgbanaka intramolecular - mmeghe nke chelator anhydrides ma ọ bụ esters na-arụ ọrụ tupu njikọ, na-ekepụta usoro ndị na-adịghị arụ ọrụ ma ọ bụ na-adịghị ike mgbagwoju anya.
- Chọpụta nsi ọla: Mmetọ site na ion metal na-abụghị redioactive (dị ka Fe³, Zn², Ku²⁺, ma ọ bụ Al³) site na reagents, iko iko, ma ọ bụ ogidi ọcha. Ọla ndị a na-achọpụta na-ejide ngwa ngwa chelators macrocyclic, igbochi ọgwụgwọ radiometal incorporation.
Nyocha nyocha akwadoro
- Tandem LC-MS/MS Peptide Mapping: Mee nkewa na-akpata nkukota (CID) ma ọ bụ Mgbasa Nfefe Eletrọn (ETD) tandem mass spectrometry ka ịhazi ion peptide peptide wee maapụta kpọmkwem ọnọdụ amino acid nke chelator..
- Mwepu/Ionization Laser na-enyere Matrix aka (MALDI-TOF-MS): Nyochaa ngwa ngwa nkesa arọ molekụla wee gosi na enweghị ụdị ụdị adduct zuru oke.
- Spectrometry Plasma Mass Spectrometry jikọtara ọnụ (ICP-MS): Ogbe ihe nleba anya maka ọkwa sub-ppm nke mmetọ ọla ngbanwe na-asọ mpi tupu akara redio..
⚠️ Ịdọ aka ná ntị: Otu akụkụ kwa nde (ppm) ọkwa nke Iron (Fe³) ma ọ bụ Zinc (Zn²) N'ime ogbe precursor nwere ike ibelata mkpụrụ kemịkalụ redio karịa karịa 40% n'ihi nchikota asọmpi nke ọma karịa Lutetium-177 ma ọ bụ Actinium-225.
Ebe nkọwapụta ndị na-ere ahịa
- Regioselectivity: 100% Mgbakwụnye saịtị akọwapụtara site na tandem MS/MS nkewa.
- Ụdị ịdị ọcha nke nwere otu ọnụ: > 98.0% mono-chelator ọdịnaya; di-chelator ụdị < 0.2%.
- Chelator efu anaghị emeghachi omume: < 0.5% mpaghara.
- Chọpụta ọdịnaya ọla dị arọ (Fe, Zn, Ku, Pb): < 0.1 ppm onye, < 0.5 ngụkọta ppm tụrụ site na ICP-MS.
Maka chemistries bioconjugation pụrụ iche, tinye n'ọrụ raara onwe ya nye njikọ chelator kpọmkwem saịtị Nrụ ọrụ na-ekwe nkwa stoichiometry ziri ezi ma na-ewepụ ntinye eriri akụkụ na-abụghị nke akọwapụtara..
Ọgwụ 3: Ịdị ọcha redio (RCP) & Ụlọ ọrụ Isotope Incorporation
Ozugbo etinyere conjugate peptide-chelator na radionuclide (eg., 177LuCl₃ ma ọ bụ 225AcNO₃), na-akwado njikọ isotope na ịdị ọcha redio (RCP) bụ isi ihe ntọhapụ chọrọ maka nkwadebe rediopharmaceutical.
Ụdị ọdịda nkịtị
- Mgbakwụnye Radiometal ezughị ezu: Mkpụrụ kemịkalụ redio dị ala na-ahapụ enweghị mgbagwoju anya, free radionuclide na ngwọta, nke na-eduga n'ịchịkọta akụkụ ahụ ndị na-apụ apụ (eg., ụmị ọkpụkpụ suppression si free 177Lu ma ọ bụ free 225Ac ire ere ụmụ nwanyị).
- Colloidal Radiometal Formation: Radiometals na-emepụta colloid hydroxide na-adịghị edozi na pH dị elu, nke adsorb na mgbidi vial ma ọ bụ na-anakọta na imeju n'oge nchịkwa vivo.
- Redio-TLC karịrị akarị: Na-adabere naanị na Chromatography nke dị obere ngwa ngwa (Radio-ITLC) maka ntọhapụ ule. Radio-ITLC na-adakarị ike idozi iberibe rediolytic ma ọ bụ obere ngwaahịa mmebi peptide sitere na redioligand akpọchiri akpọchi., na-eduga na-ezighị ezi-ezi nsonaazụ.
Nyocha nyocha akwadoro
- Radio-HPLC / Radio-UHPLC nwere ndị na-achọpụta redio n'ịntanetị: Jikọọ chromatography mmiri dị elu na gamma, beta, ma ọ bụ nchọpụta redio ndakọrịta. Dị ka nkọwa zuru ezu na e bipụtara nnyocha na Usoro nyocha Radio-HPLC maka njikwa mma redio, Radio-HPLC bụ iwu nke ikewapụta ngwaahịa mkpochapụ rediolytic na conjugates akpọrọ redio na-emebibeghị..
- Dual-System Radio-ITLC: Jiri sistemụ mkpanaaka abụọ/ọdụ ọdụ abụọ (eg., Silica gel ITLC na Ammonium Acetate:Methanol maka metal free, na Citrate buffer maka ụdị colloidal) dịka nlele nyocha nke abụọ ngwa ngwa.
Ebe nkọwapụta ndị na-ere ahịa
- Radio-HPLC Radiochemical ịdị ọcha: ≥ 95.0% maka ntọhapụ (≥ 98.0% ezubere iche maka nchịkwa ụlọ ọgwụ).
- Nkebi nke Radionuclide efu: < 1.0% ngụkọta ọrụ.
- Colloidal / Nkebi irighiri: < 1.0% ngụkọta ọrụ.
Ọgwụ 4: Radiolytic kwụsie ike & Iguzosi ike n'ezi aha mgbe e mesịrị
Therapeutic alfa na beta emitters na-edobe nnukwu radieshon ionizing mpaghara. Ike a na-emepụta ụdị oxygen na-emeghachi omume (ROS)- dị ka hydroxyl radicals (•OH), hydrated electrons, na oxygen singlet—nke na-awakpo ọkpụkpụ azụ peptide na agbụ akụkụ amino acid ozugbo.
Radionuclide ire ere (177Lu / 225Ac) → Ọgbọ ROS → Oxidation akụkụ-Chain (Met/Trp/His)
→ Scission ọkpụkpụ azụ & Na Vivo Dechelation
Ụdị ọdịda nkịtị
- Ọkpụkpụ azụ Radiolytic: Mwakpo radical na-ebute nkwụsị nke peptide amide bond n'ime awa nke akara, na-emepụta iberibe redio ndị na-adịghị arụ ọrụ ma ọ bụ na-egbu egbu.
- Akụkụ-Chain Oxidation: Methionine thioether oxidation ka sulfoxide/sulfone, ma ọ bụ Tryptophan pyrrole mgbanaka oxidation, nke na-ebelata nke ukwuu njikọ njikọ nnabata.
- Na Vivo Dechelation & Transmetallation: Mmebi radieshon na mgbanaka chelator ma ọ bụ nkwụsi ike nke nhazi na-eduga na mfu isotope na mgbasa. Dị ka ọ pụta ìhè na nyocha sayensị na chelator kwụsie ike na transmetallation ize ndụ nyocha, ogige ndị na-akwụsighị ike na-eduga na ụmị ọkpụkpụ siri ike na-apụ apụ na nsí gbasara akụrụ.
Nyocha nyocha akwadoro
- Nnwale nkwụsi ike nke oge: Nyochaa ịdị ọcha nke kemịkalụ redio site na Radio-HPLC n'oge akọwapụtachara akara ngosi (t = 0, 2, 4, 24, na 48 awa) n'okpuru ụlọ okpomọkụ na ọnọdụ nchekwa.
- Ọmụmụ ihe gbasara radical Scavenger: Nyochaa arụmọrụ nchebe nke ndị na-egbochi radical free - dị ka ascorbic acid, Gentisic acid, na Ethanol-n'ụdị ịta ahụhụ dị iche iche.
- Na Vitro Plasma Stability & Jide njide: Ntinye n'ime ọbara mmadụ na 37 Celsius C na-esochi nyocha nke njide radioligand asọmpi iji chọpụta nrụzi njikọ njikọ. (Kd).
Maka ndụmọdụ: Na-eme nnwale nrụgide redio mgbe niile na oke ọrụ volumetric (eg., 50-100 MBq / ml) n'oge nkwenye nyocha. Ngwunye nkwụsi ike na ọrụ nyocha dị ala nwere ike ịda ngwa ngwa na mkpokọta usoro ọgwụgwọ.
Ebe nkọwapụta ndị na-ere ahịa
- Nlekọta ịdị ọcha nke redio: ≥ 90.0% RCP na 24 awa post-labeling; ≥ 85.0% na 48 awa na okpomọkụ nchekwa akwadoro.
- Ụdị Peptide oxidized: < 2.0% mkpokọta ọnụ ọgụgụ kacha elu n'ihu ndị radical scavengers kachasị.
- Njide njikọ nke nnabata: Kd n'ime okpukpu abụọ nke ọkọlọtọ ntụ ntụ oyi na-enweghị ọkụ.
Usoro nhazi na-emesi ike na nkwado nyocha zuru oke ga-adakọrịrị na Agencylọ Ọrụ Ọgwụ na Europe ntuziaka usoro maka adịghị ọcha peptide sịntetik na nkọwapụta, n'ịhụ na nkwụsi ike nke bu ụzọ na ụzọ nyocha kwekọrọ na atụmanya usoro iwu mba ụwa.
Nchịkọta nkọwapụta RLT Peptide QC zuru oke
| Ike nyocha | Ụdị ọdịda nke mbụ | Nyocha nyocha akwadoro | Onye na-ere ahịa / Oke nkọwa mwepụta batch |
|---|---|---|---|
| Peptide Precursor ịdị ọcha | Na-ejikọta usoro nhichapụ, diastereomers, Nsi nke TFA Mmepụta Peptide | Orthogonal RP-HPLC (C18 & Phenyl-Hexyl), LC-ESI-HRMS, Ion Chromatography | HPLC ịdị ọcha ≥ 95.0% (IND: ≥ 98.0%); Otu adịghị ọcha < 0.5%; TFA < 1.0% |
| Nkewa saịtị njikọ | Regioisomeric miscoupling, over-conjugation, chelator hydrolysis | Tandem LC-MS/MS (Maapụ CID/ETD), MALDI-TOF-MS | 100% Regioselectivity; Mono-chelator > 98.0%; Chelator anaghị emeghachi omume < 0.5% |
| Nyocha igwe nchọta | Nsi chelator site na ion asọmpi (Fe³, Zn², Ku²⁺) | ICP-MS trace elemental analysis | Fe, Zn, Ku < 0.1 ppm onye, < 0.5 ngụkọta ppm |
| Ịdị ọcha redio (RCP) | Mgbakwụnye redio metal ezughị ezu, free isotop toxicity | Radio-HPLC nwere ihe nchọta gamma/beta, Dual-System Radio-ITLC | Radio-HPLC RCP ≥ 95.0% (Ebumnuche: ≥ 98.0%); Radiometal efu < 1.0% |
| Radiolytic kwụsie ike | Mgbawa amide na-ebute radieshon, Met/Trp oxidation | Radio-HPLC nke oge (0– 48 h), Mbulite scavenger radical | RCP ≥ 90.0% na 24 h post-labeling; Ụdị oxidized < 2.0% |
Mmekọrịta ya na ndị otu mmepe Peptide pụrụ iche
Ịtụ anya ihe ịma aka nyocha n'oge mmalite na-agbanwe nrụpụta rediopharmaceutical site na usoro nnwale-na njehie na-enweghị atụ ka ọ bụrụ nke enwere ike imepụtagharị., ọnụ ọgụgụ-njikere sayensị.
Mgbe ị na-akwalite ndị na-achọ ọgwụ redio site na nchọpụta ebumnuche gaa na ọmụmụ ihe na-enyere IND aka, leveraging a pụrụ iche peptide CRO na usoro mmepe usoro na-eme ka njikarịcha usoro ahụ, bioconjugation pụrụ iche saịtị, na njirimara nyocha siri ike ka etinyere ozugbo na kemistri gị, mmepụta ihe, na njikwa (CMC) kpuchie.
Mgbanwe MOL na-enye njikọ peptide omenala na njedebe na njedebe yana ọrụ mgbagwoju anya bioconjugation n'ime klaasị 100 gburugburu ime ụlọ na-adịghị ọcha. Akwadoro site na LC-MS/MS dị elu, HPLC orthogonal, na nyocha nyocha zuru oke, Ndị otu anyị na-enye ndị mmepe biopharma ike ịnapụta ultra-ọcha, precursors rediopharmaceutical jikọtara nke ọma nwere nghọta nyocha zuru oke.
Ajụjụ a na-ajụkarị (FAQ)
Kedu ihe kpatara ịdị ọcha HPLC naanị ezughi oke maka precursors peptide radiopharmaceutical?
Ọkọlọtọ HPLC na-atụ nnabata UV na 214 nm ma ọ bụ 220 nm, nke na-egosipụta nnabata azụ azụ peptide mana enweghị ike ịmata ọdịiche dị n'etiti regioisomers ma ọ bụ kwado saịtị mgbakwunye chelator.. Ọzọkwa, Ịdị ọcha UV anaghị ekwupụta maka mmetọ ọla na-adịghị anabata ya (dị ka Fe³⁺ ma ọ bụ Zn²⁺) ma ọ bụ mgbochi TFA, Ha abụọ na-emebi mkpụrụ akara redio na nchekwa ekwentị.
Kedu ka Radio-HPLC si dị iche na Radio-ITLC na nyocha ịdị ọcha nke redio?
Radio-ITLC na-ekewa ogige dabere na njem dị mfe na warara, nke dị mma maka nlele ọsọ ọsọ/nyocha ọdịda nke radiometal efu. Agbanyeghị, Radio-ITLC enweghị mkpebi chromatographic chọrọ iji kewapụ peptides akara redio na-adịghị emebi emebi site na obere iberibe mbibi rediolytic ma ọ bụ ụdị oxidized.. Radio-HPLC na-eji kọlụm chromatography mmiri mmiri jikọtara ya na ihe nchọpụta radieshon dị n'ịntanetị iji dozie na tụọ ụdị ụdị redio niile ahaziri nke ọma..
Kedu ihe mkpofu radical kacha dị irè na igbochi mmebi nke rediolytic?
Ascorbic acid, gentisic acid, na ethanol bụ ndị na-enyocha rediolytic kachasị mma maka ọgwụgwọ redioligand. Ha na-eme ngwa ngwa site n'ịkwụsị radicals hydroxyl na hydrated electrons emepụtara n'oge radiolysis tupu radicals ahụ enwee ike imeghachi omume na ihe fọdụrụ peptide nwere mmetụta. (dị ka methionine, Tryptophan, na Histidine) ma ọ bụ ọkpụkpụ azụ chelator.
Kedu ka esi echekwa peptides precursor iji kwado nkwụsi ike chelator ogologo oge?
Peptide-chelator conjugates (dị ka DOTA-TATE ma ọ bụ PSMA-617 precursors) Ekwesịrị ịchekwa lyophilized dị ka aliquots na-adịghị mma n'okpuru gas inert (nitrogen ma ọ bụ argon) na -20 ° C ruo -80 ° C. Izere okirikiri ntu oyi ugboro ugboro yana ichebe ihe mmalite site na mmiri ikuku na-egbochi mmebi hydrolytic nke macrocyclic chelators na oxidation n'akụkụ oxidation tupu akara redio..
